Delgocitinib Cream Significantly Improves Chronic Hand Eczema in Trial
The trial met its primary endpoint with a significantly larger proportion of delgocitnib-treated patients achieving treatment success.
Diagnosis & Disease Information
Dupixent Approved for Adults With Prurigo Nodularis
The approval was based on data from the phase 3 PRIME and PRIME2 trials.
Roflumilast Foam Looks Promising in Seborrheic Dermatitis Trial
Roflumilast is a highly potent and selective phosphodiesterase type 4 inhibitor.
Dupilumab Gets Priority Review for Prurigo Nodularis
The sBLA is supported by data from the phase 3 PRIME2 and PRIME trials that assessed dupilumab in patients 18 years of age and older with prurigo nodularis.
Optimal Difelikefalin Dose Reported for Pruritus in Hemodialysis
In a previous US phase 2 trial, no clear dose response was observed with difelikefalin.
Significant Improvements Observed With Dupilumab in Prurigo Nodularis Trial
The phase 3 PRIME study evaluated dupilumab in 151 adults with inadequately controlled prurigo nodularis.
New Drugs Approved in 2021
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Dupilumab Reduced Itch, Skin Lesions in Patients With Prurigo Nodularis
The randomized, double-blind, placebo-controlled, parallel-group PRIME2 study included 160 patients with prurigo nodularis.
Korsuva Approved for Chronic Kidney Disease-Associated Pruritus
The approval was based on data from the pivotal phase 3 KALM-1 and KALM-2 trials, as well as data from an additional 32 clinical studies.
